Compounded Tirzepatide in 2026: Where It Stands Legally
Key Takeaways
- Compounded tirzepatide faces the same legal framework as semaglutide — 503A patient-specific compounding is the viable pathway
- Tirzepatide is still on the FDA drug shortage list as of mid-2026 — giving 503B facilities more legal room than semaglutide
- If tirzepatide comes off the shortage list, expect the same 503B restrictions that hit semaglutide
- Eli Lilly has been less aggressive than Novo Nordisk in legal action — but that could change
- Compounded tirzepatide is available in injectable and oral formats through telehealth providers
While semaglutide has dominated the compounding legal headlines, tirzepatide (the active ingredient in Mounjaro and Zepbound) has its own trajectory. Here's where it stands in 2026.
Tirzepatide vs. Semaglutide: Legal Status
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| FDA shortage status | Off shortage list | Still on shortage list (mid-2026) |
| 503A compounding | Legal with patient Rx | Legal with patient Rx |
| 503B compounding | Restricted | Permitted (during shortage) |
| Manufacturer legal action | Aggressive (Novo Nordisk) | Less aggressive (Eli Lilly) — so far |
| Compounded formats | Injectable, oral, sublingual | Injectable, oral |
What Happens When Tirzepatide Leaves the Shortage List?
The semaglutide playbook suggests what will happen: 503B facilities lose their bulk-compounding basis, legal pressure increases, and the market consolidates around 503A patient-specific providers. This transition could happen in late 2026 or 2027 — the exact timing depends on Lilly's manufacturing capacity and FDA assessment.
Telos Rx
TirzCompounded tirzepatide. First month from $40; ongoing $160-249/mo.
Compounded tirzepatide — $365 CPA.
MadeMed
Oral TirzCompounded oral tirzepatide tablets.
Compounded oral tirzepatide — $89/mo quarterly.
GobyMeds
BudgetInjectable compounded sema $99/mo, tirz $133/mo. Direct affiliate.
Injectable tirz $133/mo.
Compounded tirzepatide has more legal breathing room than semaglutide in 2026 because it's still in shortage. But that window will close. If you're using compounded tirzepatide, make sure your provider uses a 503A patient-specific model so your access survives the eventual shortage-list removal.
GLP-1 Compound Pharmacy Editorial
Independent compounding pharmacy research. 503A/503B analysis, safety verification, regulatory tracking. Not medical advice.